St. Petersburg, FL – November 7, 2022 – Resolve Therapeutics, pioneering first-in-class, targeted, safe therapies for underserved autoimmune diseases, today announced that its phase 2 clinical trial of RSLV-132 in patients with long covid has been fully enrolled (NCT04944121).
A New Approach to Treating Lupus & Sjögren’s
Resolve Therapeutics is pioneering first-in-class compounds for Systemic Lupus Erythematosus (SLE; “lupus”) and primary Sjögren’s syndrome (pSS). Our lead product candidate, RSLV-132, has the potential to prevent the inflammation that causes the debilitating symptoms of autoimmune diseases. The Company is evaluating RSLV-132 in a Phase 2 lupus study, and is preparing to initiate registration studies with RSLV-132 in patients with Sjögren’s syndrome.
Our Novel Nuclease Platform
Resolve is developing a novel treatment to remove pro-inflammatory RNA molecules from the blood of patients with autoimmune diseases, including lupus and Sjögren’s. This therapeutic approach is supported by two decades of research validating that RNA held in circulation leads to chronic inflammation. By leveraging RNase, a safe molecule already found in blood, RSLV-132 digests RNA without being immunogenic or immunosuppressive, unlike many molecules currently in development for autoimmune diseases.
The Unmet Medical Need in Lupus and Sjögren’s Syndrome
Lupus and Sjögren’s syndrome, which primarily affect women, occur when the immune system attacks its own organs. There is no cure for lupus, and no approved therapy available for Sjögren’s syndrome. Historically, these diseases have been under-researched and under-funded. Resolve’s first-in-class biologic has the potential to meet this critical unmet medical need in women’s health.